Bain Capital Life Sciences (BCLS) has raised its fourth fund, with approximately $3bn of total commitments, including $2.5bn of outside commitments from existing and new investors, and the balance from Bain Capital partners, employees, and affiliates.
According to a press statement, the new fund will invest scale capital globally in transformative medicines, medical devices, diagnostics, and life sciences tools that have the potential to improve the lives of patients with unmet medical needs. The BCLS investment team includes more than 25 professionals, as well as a distinguished group of advisors, who together bring extensive private and public market investing experience, operating and consulting experience, and deep scientific and medical insights to each investment.
Since its inception in 2016, BCLS has raised approximately $6.7bn and invested in more than 70 companies that have initiated more than 100 clinical trials, achieved 16 regulatory authority approvals, and launched numerous products.
